Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors

• Published in: Human mutation Vol. 23; no. 2; pp. 134 - 146
• Main Authors: Upadhyaya, Meena, Han, Song, Consoli, Claudia, Majounie, Elisa, Horan, Martin, Thomas, Nick S., Potts, Christopher, Griffiths, Sian, Ruggieri, Martino, von Deimling, Andreas, Cooper, David N.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.02.2004; Hindawi Limited
• Subjects: Alleles; Astrocytoma - genetics; Central Nervous System Neoplasms - genetics; DNA Mutational Analysis - methods; DNA, Neoplasm - genetics; Genes, Neurofibromatosis 1; Genes, p16; Genes, p53 - genetics; Genome, Human; Germ-Line Mutation - genetics; germline, somatic mutations; Humans; Loss of Heterozygosity - genetics; Lymphocytes - chemistry; Mutation - genetics; Nerve Sheath Neoplasms - genetics; Neurofibroma - genetics; Neurofibromatosis 1 - genetics; neurofibromatosis type 1; Neurofibromin 1 - genetics; NF1; Precancerous Conditions - genetics; Pseudogenes - genetics; Trinucleotide Repeat Expansion - genetics; tumor, benign; tumor, malignant
• ISSN: 1059-7794; 1098-1004
• DOI: 10.1002/humu.10305

One of the main features of neurofibromatosis type 1 (NF1) is benign neurofibromas, 10–20% of which become transformed into malignant peripheral nerve sheath tumors (MPNSTs). The molecular basis of NF1 tumorigenesis is, however, still unclear. Ninety‐one tumors from 31 NF1 patients were screened for gross changes in the NF1 gene using microsatellite/restriction fragment length polymorphism (RFLP) markers; loss of heterozygosity (LOH) was found in 17 out of 91 (19%) tumors (including two out of seven MPNSTs). Denaturing high performance liquid chromatography (DHPLC) was then used to screen 43 LOH‐negative and 10 LOH‐positive tumors for NF1 microlesions at both RNA and DNA levels. Thirteen germline and 12 somatic mutations were identified, of which three germline (IVS7–2A>G, 3731delT, 6117delG) and eight somatic (1888delG, 4374‐4375delCC, R2129S, 2088delG, 2341del18, IVS27b–5C>T, 4083insT, Q519P) were novel. A mosaic mutation (R2429X) was also identified in a neurofibroma by DHPLC analysis and cloning/sequencing. The observed somatic and germline mutational spectra were similar in terms of mutation type, relative frequency of occurrence, and putative underlying mechanisms of mutagenesis. Tumors lacking mutations were screened for NF1 gene promoter hypermethylation but none were found. Microsatellite instability (MSI) analysis revealed MSI in five out of 11 MPNSTs as compared to none out of 70 neurofibromas (p=1.8 × 10−5). The screening of seven MPNSTs for subtle mutations in the CDKN2A and TP53 genes proved negative, although the screening of 11 MPNSTs detected LOH involving either the TP53 or the CDKN2A gene in a total of four tumors. These findings are consistent with the view that NF1 tumorigenesis is a complex multistep process involving a variety of different types of genetic defect at multiple loci. Hum Mutat 23:134–146, 2004. © 2003 Wiley‐Liss, Inc.